Jan 13, 2025
Akebia Therapeutics Announces Multiple Positive Business Updates
Jan 02, 2025
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 18, 2024
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 03, 2024
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Nov 14, 2024
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Nov 12, 2024
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 07, 2024
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Nov 01, 2024
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
Nov 01, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 22, 2024
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Oct 15, 2024
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Oct 10, 2024
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
Oct 07, 2024
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Sep 05, 2024
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
Sep 03, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 08, 2024
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Aug 02, 2024
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
Aug 01, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 11, 2024
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
Jun 27, 2024
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference